Urgent.News

What's breaking now, across thousands of outlets.

Culture

Sustained reductions in inflammatory markers seen with novel antibody drug

The interleukin-6 (IL-6) antibody pacibekitug produced sustained reductions in inflammatory biomarkers in patients with chronic kidney disease at high inflammatory risk, according to results from the Phase II TRANQUILITY trial presented in a Hot Line session at ESC Congress 2026.

Sustained reductions in inflammatory markers seen with novel antibody drug

We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.

Read the original at medicalxpress.com →

More in Culture

More from Monday 31 August →